Clinical accuracy of instrument-based SARS-CoV-2 antigen diagnostic tests: a systematic review and meta-analysis
Katharina Manten,
No information about this author
Stephan Katzenschlager,
No information about this author
Lukas E. Brümmer
No information about this author
et al.
Virology Journal,
Journal Year:
2024,
Volume and Issue:
21(1)
Published: April 29, 2024
During
the
COVID-19
pandemic,
antigen
diagnostic
tests
were
frequently
used
for
screening,
triage,
and
diagnosis.
Novel
instrument-based
(iAg
tests)
hold
promise
of
outperforming
their
instrument-free,
visually-read
counterparts.
Here,
we
provide
a
systematic
review
meta-analysis
SARS-CoV-2
iAg
tests'
clinical
accuracy.
Language: Английский
Clinical accuracy of instrument-based SARS-CoV-2 antigen diagnostic tests: A systematic review and meta-analysis
Katharina Manten,
No information about this author
Stephan Katzenschlager,
No information about this author
Lukas E. Brümmer
No information about this author
et al.
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 5, 2024
Abstract
Background
During
the
COVID-19
pandemic,
antigen
diagnostic
tests
were
frequently
used
for
screening,
triage,
and
diagnosis
because
they
are
faster
less
expensive
than
molecular
tests,
despite
being
sensitive
terms
of
analytical
clinical
performance.
Novel
instrument-based
(iAg
tests)
hold
promise
outperforming
their
instrument-free,
visually-read
counterparts.
Here,
we
provide
a
systematic
review
meta-analysis
SARS-CoV-2
iAg
tests’
accuracy.
Methods
We
systematically
searched
MEDLINE
(via
PubMed),
Web
Science,
medRxiv,
bioRxiv
articles
published
before
November
7th,
2022,
evaluating
accuracy
detection.
performed
random
effects
to
estimate
sensitivity
specificity
QUADAS-2
tool
assess
study
quality
risk
bias.
Results
compiled
data
from
117
studies
involving
95,181
individuals
assessing
24
commercial
tests.
The
varied
in
bias
but
showed
high
applicability.
Of
99
assessed
meta-analysis,
pooled
compared
testing
paired
NP
swab
sample
76.7%
(95%
CI
73.5
79.7)
98.4%
98.0
98.7),
respectively.
Out
eight
with
sufficient
test-specific
only
LumiraDx
satisfied
WHO's
standards.
Higher
was
noted
viral
load
(99.6%
[95%
96.8
100]
at
Ct-level
≤
20)
within
first
week
symptom
onset
(84.6%
78.2
89.3]),
did
not
differ
between
conducted
as
per
manufacturer’s
instructions
those
differently,
or
point-of-care
lab-based
testing.
Conclusion
Our
reveals
that
tests'
increases
lower
Ct-values,
proxy
load,
onset,
enabling
reliable
identification
most
cases.
While
these
characteristics
similar
instrument-free
diagnostics,
different
types
might
allow
standardized
result
interpretation
curb
human
error,
automated
reporting,
upscaling
test
runs
additional
functions,
such
indication
levels.
Depending
on
setup,
can
be
point
care
laboratory
high-throughput.
Language: Английский
Current Perspectives on Antigen Testing in Respiratory Infections
The Pediatric Infectious Disease Journal,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 7, 2024
Language: Английский